These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

728 related items for PubMed ID: 22533524

  • 21. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura.
    Zeng Y, Duan X, Xu J, Ni X.
    Cochrane Database Syst Rev; 2011 Jul 06; 2011(7):CD008235. PubMed ID: 21735426
    [Abstract] [Full Text] [Related]

  • 22. Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland.
    Lee D, Thornton P, Hirst A, Kutikova L, Deuson R, Brereton N.
    Appl Health Econ Health Policy; 2013 Oct 06; 11(5):457-69. PubMed ID: 23857462
    [Abstract] [Full Text] [Related]

  • 23. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
    Lassandro G, Palladino V, Vecchio GCD, Palmieri VV, Corallo PC, Faienza MF, Giordano P.
    Endocr Metab Immune Disord Drug Targets; 2021 Oct 06; 21(3):397-406. PubMed ID: 32473624
    [Abstract] [Full Text] [Related]

  • 24. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
    Mori M, Kato M, Koh K, Hanada R.
    Rinsho Ketsueki; 2015 May 06; 56(5):511-3. PubMed ID: 26062675
    [Abstract] [Full Text] [Related]

  • 25. Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim.
    Al-Samkari H, Van Cott EM, Kuter DJ.
    Ann Hematol; 2019 Mar 06; 98(3):581-588. PubMed ID: 30446804
    [Abstract] [Full Text] [Related]

  • 26. Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP).
    Sanz MA, Aledort L, Mathias SD, Wang X, Isitt JJ.
    Value Health; 2011 Jan 06; 14(1):90-6. PubMed ID: 21211490
    [Abstract] [Full Text] [Related]

  • 27. Immune thrombocytopenia: Pathophysiology and impacts of Romiplostim treatment.
    Semple JW, Schifferli A, Cooper N, Saad H, Mytych DT, Chea LS, Newland A.
    Blood Rev; 2024 Sep 06; 67():101222. PubMed ID: 38942688
    [Abstract] [Full Text] [Related]

  • 28. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
    Neunert CE, Rose MJ.
    Blood Adv; 2019 Jun 25; 3(12):1907-1915. PubMed ID: 31239245
    [Abstract] [Full Text] [Related]

  • 29. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
    Kuter DJ, Macahilig C, Grotzinger KM, Poston SA, Wang PF, Dawson KL, Ward M.
    Int J Hematol; 2015 Mar 25; 101(3):255-63. PubMed ID: 25586660
    [Abstract] [Full Text] [Related]

  • 30. Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview.
    Vibor M, Rogulj IM, Ostojic SK.
    Cardiovasc Hematol Disord Drug Targets; 2017 Jul 04; 17(1):38-51. PubMed ID: 28034281
    [Abstract] [Full Text] [Related]

  • 31. Moving towards a new era in the management of chronic immune thrombocytopenia.
    Wadenvik H, Olsson B.
    Ann Hematol; 2010 Jul 04; 89 Suppl 1():87-93. PubMed ID: 20339846
    [Abstract] [Full Text] [Related]

  • 32. Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura.
    Newland A.
    Eur J Haematol Suppl; 2009 Mar 04; (71):20-5. PubMed ID: 19200304
    [Abstract] [Full Text] [Related]

  • 33. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.
    Khellaf M, Michel M, Quittet P, Viallard JF, Alexis M, Roudot-Thoraval F, Cheze S, Durand JM, Lefrère F, Galicier L, Lambotte O, Panelatti G, Slama B, Damaj G, Sebahoun G, Gyan E, Delbrel X, Dhedin N, Royer B, Schleinitz N, Rossi JF, Mahévas M, Languille L, Bierling P, Godeau B.
    Blood; 2011 Oct 20; 118(16):4338-45. PubMed ID: 21832276
    [Abstract] [Full Text] [Related]

  • 34. Successful treatment of Immune Thrombocytopenic Purpura (ITP) with the thrombopoietin-mimetic romiplostim.
    Meletis J, Katsandris A, Raptis SD, Mantzourani M.
    Med Sci Monit; 2010 Aug 20; 16(8):CS100-2. PubMed ID: 20671616
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Romiplostim: a review of its use in immune thrombocytopenia.
    Keating GM.
    Drugs; 2012 Feb 12; 72(3):415-35. PubMed ID: 22316355
    [Abstract] [Full Text] [Related]

  • 37. Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia.
    Kuter DJ, Tarantino MD, Lawrence T.
    Blood Rev; 2021 Sep 12; 49():100811. PubMed ID: 33781612
    [Abstract] [Full Text] [Related]

  • 38. Romiplostim.
    Kuter DJ.
    Cancer Treat Res; 2011 Sep 12; 157():267-88. PubMed ID: 21052962
    [Abstract] [Full Text] [Related]

  • 39. Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry.
    Doobaree IU, Newland A, McDonald V, Nandigam R, Mensah L, Leroy S, Seesaghur A, Patel H, Wetten S, Provan D.
    Eur J Haematol; 2019 May 12; 102(5):416-423. PubMed ID: 30758874
    [Abstract] [Full Text] [Related]

  • 40. A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists.
    Dolph M, Roy A, Bhor M, Hearnden J, Kwon CS, Forsythe A, Tremblay G, Briggs A.
    J Comp Eff Res; 2018 Aug 12; 7(8):775-784. PubMed ID: 29848048
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.